3 minute read
The company s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo
Men with a deadly form of advanced prostate cancer who failed other treatments survived four months longer after getting an experimental, tumour-targeting radiation therapy from Swiss drugmaker Novartis (NOVN.S), data released on Thursday showed.
The company s Lu-PSMA-617 therapy boosted median overall survival (OS) to 15.3 months in patients with metastatic castration-resistant prostate cancer, according to data released at the 2021 American Society of Clinical Oncology annual meeting.
That compared with 11.3 months for men who got standard care.
NOVARTIS AG CHF0.50(REGD)
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase
1
In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and retinal vascular occlusion versus aflibercept
Beovu (brolucizumab) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept